Peter Pack, a former partner at EMBL Ventures, has become chief executive of Crescendo Biologics Ltd, which is developing new antibody-based therapeutics for cancer. Dr Pack has been an observer on Crescendo’s board since EMBL participated in a Series A funding round for the company in 2014. Besides working in finance, Dr Pack has had executive-level experience in medical devices and diagnostics, as well as in antibody development. He has worked in the life science sector for 23 years, of which 14 have been in CEO or managing director positions.
Crescendo Biologics announced the appointment on 14 October 2015.
Copyright 2015 Evernow Publishing Ltd